These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE; Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913 [TBL] [Abstract][Full Text] [Related]
7. Decreased proportions of CD4 + IL17+/CD4 + CD25 + CD127- and CD4 + IL17+/CD4 + CD25 + CD127 - FoxP3+ T cells in children with autoimmune thyroid diseases (.). Bossowski A; Moniuszko M; Idźkowska E; Grubczak K; Singh P; Bossowska A; Diana T; Kahaly GJ Autoimmunity; 2016 Aug; 49(5):320-8. PubMed ID: 27206624 [TBL] [Abstract][Full Text] [Related]
8. [Current thyroid diagnostics and therapy in disorders of fertility and in pregnancy]. Fink HJ; Hintze G Med Klin (Munich); 2006 Aug; 101(8):645-52; quiz 653-4. PubMed ID: 16896571 [No Abstract] [Full Text] [Related]
9. Are pituitary and thyroid function tests useful for the monitoring of antithyroid drug treatment and the post therapeutic control of Graves' disease? Jaffiol C; Baldet L; Castelnau P; Papachristou C; Lapinski H; Rouaud R Horm Res; 1987; 26(1-4):137-45. PubMed ID: 2439427 [TBL] [Abstract][Full Text] [Related]
10. Salivary Alterations in Autoimmune Thyroid Diseases: A Systematic Review. Ortarzewska M; Nijakowski K; Kolasińska J; Gruszczyński D; Ruchała MA; Lehmann A; Surdacka A Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981758 [TBL] [Abstract][Full Text] [Related]
11. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. Kaguelidou F; Alberti C; Castanet M; Guitteny MA; Czernichow P; Léger J; J Clin Endocrinol Metab; 2008 Oct; 93(10):3817-26. PubMed ID: 18628515 [TBL] [Abstract][Full Text] [Related]
13. Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Koornstra JJ; Kerstens MN; Hoving J; Visscher KJ; Schade JH; Gort HB; Leemhuis MP Neth J Med; 1999 Nov; 55(5):215-21. PubMed ID: 10593131 [TBL] [Abstract][Full Text] [Related]
14. A patient-specific treatment model for Graves' hyperthyroidism. Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665 [TBL] [Abstract][Full Text] [Related]
15. Management of recurrent hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy. Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K J Endocrinol Invest; 1995 Jun; 18(6):415-9. PubMed ID: 7594234 [TBL] [Abstract][Full Text] [Related]
16. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Glinoer D; de Nayer P; Bex M; Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213 [TBL] [Abstract][Full Text] [Related]
17. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report. Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094 [TBL] [Abstract][Full Text] [Related]
18. Rational management of thyroid auto-immune disease. Adams DD N Z Med J; 1974 Dec; 80(529):486-9. PubMed ID: 4141486 [No Abstract] [Full Text] [Related]
20. The clinical phenotype of Graves' disease occurring as an isolated condition or in association with other autoimmune diseases. Rotondi M; Virili C; Pinto S; Coperchini F; Croce L; Brusca N; Centanni M; Chiovato L J Endocrinol Invest; 2020 Feb; 43(2):157-162. PubMed ID: 31407208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]